The secret is out: South Carolina is a great place to live. Our state’s natural beauty is what makes us special, and others want to share in that. We welcome newcomers who feel the love and ...

COLUMBIA, S.C. — South Carolina lawmakers are looking for ways to manage the state’s rapid growth, and a bill moving through the Senate aims to give local governments more control over when new ...

Trends come and go, but there are still a few heritage fashion essentials that never go out of style. After all, there’s nothing that hits like the classics: straight-leg jeans, a white T-shirt, a ...

It was a night of breaking world records, 23 to be precise, but none of them happened on the field. The late former Indianapolis Colts owner Jim Irsay was known for his collection of prized items, and ...

Shahid Kapoor's 'O'Romeo' has completed a week since its release in theaters. The film has been showing a downward trend from the beginning as it failed to pull the audience to the theaters. While the ...

In addition, GlassFish 8 embraces the future of concurrency in Java with support for virtual threads in its HTTP thread pools and managed executors, Mihalyi said. Virtual threads support enables the ...

Abstract: Garbage collection (GC) is a critical memory management mechanism within the Java Virtual Machine (JVM) responsible for automating memory allocation and reclamation. Its performance affects ...

This story has been updated with new information. Super Bowl LX marked a historic night for music, and showcased the heart of America's political divide. The Apple Music Super Bowl 60 halftime show ...

Roblox has said that a performance of Bruno Mars's new single in the platform's user-created Steal A Brainrot mode attracted 12.8 million concurrent users, which it described as a "single artist ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell ...

Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune ...